Clinical Trial Detail

NCT ID NCT01780545
Title Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Noah Hahn, M.D.
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Apatorsen

Docetaxel

Age Groups: adult

No variant requirements are available.